Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418625 | 1.00 | CYP4F2 (0.38) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL3419503 | 1.00 | CYP4F2 (0.38) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL3417759 | 0.98 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL3417693 | 0.91 | — | — | |
| SCHEMBL11191149 | 0.83 | CYP4F2 (0.40) | CYP4F2CYP4A11 | |
| SCHEMBL11793252 | 0.82 | CYP4F2 (0.36) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 | |
| SCHEMBL3422565 | 0.81 | — | — | |
| SCHEMBL11183207 | 0.80 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| 1-Pentanol SCHEMBL27979326 | 0.76 | SMN1; SMN2 (0.40) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL12059903 | 0.76 | CYP4F2 (0.35) | CYP4F2CYP4A11LMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243037-A1 | Polysialic Acid-Polycaprolactone Micelles for Drug Delivery | SYRACUSE UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130712-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION USING THE SAME, AND RESIN CURED PRODUCT | ARCN1, APP, ADAM17 | CYP4F2 4714/4885CYP4A11 3729/4885LMNA 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.